Early bisphosphonate treatment in infants with severe osteogenesis imperfecta

Journal of Pediatrics

Volumn 149, Issue 2, 2006, Pages 174-179

  Antoniazzi, Franco ^a   Zamboni, Giorgio ^a   Lauriola, Silvana ^a   Donadi, Luisa ^a   Adami, Silvano ^a   Tatò, Luciano ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLLAGEN; COLLAGEN TYPE 1; CREATININE; NERIDRONIC ACID; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHORUS; SOMATOMEDIN C; TELOPEPTIDE;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BIRTH; BODY HEIGHT; BODY WEIGHT; BONE GROWTH; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; FEMALE; FRACTURE; HORMONE URINE LEVEL; HUMAN; INCIDENCE; INFANCY; INFANT; MALE; OSTEOGENESIS IMPERFECTA; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RADIOGRAPHY; SPINE; STATISTICAL SIGNIFICANCE; VERTEBRA BODY; VITAMIN BLOOD LEVEL;

ANTHROPOMETRY; CALCIUM; DENSITOMETRY, X-RAY; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; EARLY DIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; LUMBAR VERTEBRAE; MALE; OSTEOCALCIN; OSTEOGENESIS IMPERFECTA; PHOSPHATES; PREVALENCE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 33746386370     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2006.03.013     Document Type: Article

References (26)

1. Rauch F., and Glorieux F.H. Osteogenesis imperfecta. Lancet 363 (2004) 1377-1385
2. Antoniazzi F., Mottes M., Fraschini P., Brunelli P.C., and Tatò L. Osteogenesis imperfecta. Practical treatment guidelines. Paediatr Drugs 2; (2000) 465-488
3. Le Blanc K., Gotherstrom C., Ringden O., Hassan M., McMahon R., Horwitz E., et al. Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation 79 (2005) 1607-1614
4. Fleisch H. Bisphosphonates. Mechanisms of action. Endocr Rev 19 (1998) 80-100
5. Bembi B., Parma A., Bottega M., Ceschel S., Zanatta M., Martini C., and Ciana G. Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr 131 (1997) 622-625
6. Åström E., and Söderhäll S. Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Pediatr 87 (1998) 64-68
7. Glorieux F.H., Bishop N.J., Plotkin H., Lanque G., and Travers R. Cyclic administration of pamidronate in children's with severe osteogenesis imperfecta. N Engl J Med 339 (1998) 947-952
8. Rauch F., Plotkin H., Zeitlin L., and Glorieux F.H. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta. effect of intravenous pamidronate therapy. J Bone Miner Res 18 (2003) 610-614
9. Sakkers R., Kok D., Engelbert R., van Dongen A., Jansen M., Pruijs H., et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta. a 2-year randomised placebo-controlled study. Lancet 363 (2004) 1427-1431
10. Gatti D., Antoniazzi F., Prizzi R., Braga V., Rossini M., Tato L., et al. Intravenous neridronate in children with osteogenesis imperfecta. a randomized controlled study. J Bone Miner Res 20 (2005) 758-763
11. Plotkin H., Rauch F., Bishop N.J., Montpetit K., Ruck-Gibis J., Travers R., et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 85 (2000) 1846-1850
12. DiMeglio L.A., Ford L., McClintock C., and Peacock M. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone 35 (2004) 1038-1045
13. Sempé M., Pedron G., and Roy-Pernot M.P. Auxologie, méthode et séquences (1979), Laboratoire Théraplix, Paris
14. Sumnik Z., Land C., Rieger-Wettengl G., Korber F., Stabrey A., and Schoenau E. Effect of pamidronate treatment on vertebral deformity in children with primary osteoporosis. A pilot study using radiographic morphometry. Horm Res 61 (2004) 137-142
15. Vetter U., Pontz B., Zauner E., Brenner R.E., and Spranger J. Osteogenesis imperfecta. a clinical study of the first ten years of life. Calcif Tissue Int 50 (1992) 36-41
16. Adami S., and Zamberlan N. Adverse effects of bisphosphonates. a comparative review. Drug Safety 14 (1996) 158-170
17. Munns C.F., Rauch F., Mier R.J., and Glorieux F.H. Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone 35 (2004) 231-234
18. Adami S., Gatti D., Colapietro F., Fracassi E., Braga V., Rossini M., et al. Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 18 (2003) 126-130
19. Zeitlin L., Rauch F., Plotkin H., and Glorieux F.H. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 111 (2003) 1030-1036
20. Landsmeer-Beker E.A., Massa G.G., Maasawinkel-Mooy P.D., van de Kamp J.J., and Papapoulos S.E. Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate). Eur J Pediatr 156 (1997) 792-794
21. Chines A., Petersen D.J., Schranck F.W., and Whyte M.P. Hypercalciuria in children severely affected with osteogenesis imperfecta. J Pediatr 119 (1991) 51-57
22. Rauch F., Plotkin H., Travers R., Zeitlin L., and Glorieux F.H. Osteogenesis imperfecta types I, III, and IV. effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 88 (2003) 986-992
23. Langman C.B. Improvement of bone in patients with osteogenesis imperfecta treated with pamidronate-lessons from biochemistry. J Clin Endocrinol Metab 88 (2003) 984-985
24. Montpetit K., Plotkin H., Rauch F., Bilodeau N., Cloutier S., Rabzel M., et al. Rapid increase in grip force after start of pamidronate therapy in children and adolescents with severe osteogenesis imperfecta. Pediatrics 111 (2003) e601-e603
25. Rauch F., Travers R., Plotkin H., and Glorieux F.H. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 110 (2002) 1293-1299
26. Munns C.F., Rauch F., Travers R., and Glorieux F.H. Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta. clinical and histomorphometric outcome. J Bone Miner Res 20 (2005) 1235-1243